Drug Database
AM

amlodipine + celecoxib (Consensi / KIT 302 / KIT302)

✓ Approved

Burke Pharmaceutical · CACNA1C · Small Molecule

What is amlodipine + celecoxib?

amlodipine + celecoxib is a small molecule developed by Burke Pharmaceutical. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesConsensi, KIT 302, KIT302
CompanyBurke Pharmaceutical
Drug ClassSmall Molecule
Molecular TargetCACNA1C, PTGS2
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Burke Pharmaceutical

Mechanism of Action

Molecular Targets

amlodipine + celecoxib acts on 2 molecular targets:

CACNA1Ccalcium voltage-gated channel subunit alpha1 C (NEDHLSS, CACH2)
PTGS2prostaglandin-endoperoxide synthase 2 (hCox-2, PHS-2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

amlodipine + celecoxib is developed for 3 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Vascular disordersHypertension✓ Approved
Musculoskeletal and connective tissue disordersMusculoskeletal pain✓ Approved
Renal and urinary disordersRenal failurePreclinical

Related Research Articles

PubMedBioactive materials2026-10-20

Reprogramming pathological secretory phenotype of chondrocytes inhibits neurovascular invasion for osteoarthritis treatment.

Yuan Xiaonan X, Xiao Yao Y, Chen Cheng C, Hong Youzhi Y et al.

Pain severity in osteoarthritis (OA) often dissociates from the extent of cartilage structural damage, indicating that non-structural mechanisms contribute to symptom persistence. Here, we identify articular chondrocytes as active orchestrators of pathological neurovascular invasion through a pathogenic secretome, rather than merely passive victims of degeneration. Integrated human single-cell transcriptomic analysis reveals that OA chondrocytes undergo phenotypic reprogramming characterized by coordinated activation of angiogenic and neurotrophic programs. Functionally, inflammatory chondrocytes directly promote endothelial angiogenesis and sensory axon outgrowth, linking chondrocyte-derived signals to neurovascular invasion and sustained pain. To therapeutically target this upstream mechanism, we engineered MMP-13-responsive celecoxib-loaded hyaluronic acid methacrylate microspheres (HMPC) for disease-adaptive delivery to degenerative cartilage. HMPC suppresses chondrocyte COX-2 activity and remodels the pathological chondrocyte secretome through restoration of miR-339-5p_R-5 and miR-103-3p_R-2, thereby inhibiting angiopoietin-2 (Angpt2)-mediated angiogenesis and brain-derived neurotrophic factor (Bdnf)-driven sensory neurogenesis. In murine OA models, HMPC markedly alleviates pain-related behaviors, reduces neurovascular infiltration, and preserves joint structure. Collectively, this study supports a chondrocyte-centric framework in which reprogrammed chondrocytes govern neurovascular invasion through microRNA-dependent secretome regulation and introduces a smart biomaterial-enabled strategy with disease-modifying potential for OA pain intervention.

PMID 42898573
Read full article →
PubMedOncology and therapy2026-10-20

Multimodal Combination Treatment in a Patient-Centered Approach is Associated with Improved Outcome in Relapsed/Refractory Sarcomas in Children: A Comparative Single-Institution Real-World Analysis.

Kyr Michal M, Polaskova Kristyna K, Mudry Peter P, Dusek Vitezslav V et al.

Targeted treatment in children, especially with sarcomas, has limited utility due to small numbers of patients with driving mutations. Multimodal combination treatment and patient-centered approach combine treatment modalities administered based on comprehensive biological and empirical factors. Together, they extend precision oncology beyond a single molecular target. This is a single-institution real-world study of children and young adults diagnosed between 2004 and 2021, with relapsed/refractory and/or primary metastasizing high-risk solid tumors who underwent molecular tumor board. Patients underwent comprehensive biological examination of the tumor. A treatment recommendation was made subsequently combining empirical and biological data. All progressive/recurrent events during disease follow-up were analyzed using a hierarchical survival modeling approach combining individual patient time series in a meta-analytic framework for comparative analysis of treatment effects. A total of 93 patients were included in the analysis who experienced 189 events. Overall survival was 7.5 years. A comparative analysis utilizing event-free survival (EFS) ratio was possible in an ultra-high-risk subset of 66 patients with relapsed/progressive disease. Effectiveness was demonstrated in the treatment of sarcomas by empirical treatment (HR 0.57, p = 0.005), which consisted mainly of orally administered cyclophosphamide, vinblastine, and celecoxib, and by sunitinib or pazopanib (HR = 0.66, p = 0.032) in biologically guided administration. This study demonstrates that individualized treatment offers effective treatment options to a wide range of patients with high-risk cancers even for tumors without known high-level evidence molecular targets. We have shown that an alternative analytical approach based on the n-of-1-inspired framework is needed and applicable to demonstrate the effectiveness.

PMID 42900460
Read full article →
PubMedAmerican journal of hypertension2026-10-19

Amlodipine and Nifedipine Associations with B-Type Natriuretic Peptide in Women with Hypertension and Heart Failure with Preserved Ejection Fraction.

Harada Eisaku E, Yamada Toshihiro T, Mizuno Yuji Y, Arima Yuichiro Y et al.

Calcium channel blockers (CCBs) are frequently prescribed to manage hypertension in patients with heart failure with preserved ejection fraction (HFpEF). However, whether individual dihydropyridine agents exert uniform class effects on myocardial wall stress remains unclear. This retrospective, single-center observational study analyzed 465 consecutive patients with hypertension and HFpEF (354 women and 111 men) evaluated at Kumamoto Kinoh Hospital between May 2012 and July 2018. Multivariable linear regression models assessed associations between individual dihydropyridine CCBs (amlodipine vs. nifedipine) and plasma log-transformed B-type natriuretic peptide (lnBNP) levels. In multiple imputation models among women, adjusted differences in lnBNP relative to no-CCB were 0.236 (95% CI, 0.031 to 0.441) for nifedipine and -0.118 (95% CI, -0.273 to 0.037) for amlodipine. Direct linear contrasts in women confirmed lower lnBNP levels with amlodipine than with nifedipine (adjusted difference, -0.355; 95% CI, -0.562 to - 0.147). In men, the corresponding amlodipine-versus-nifedipine difference was -0.051 (95% CI, -0.697 to 0.595; P=0.876). The formal sex-by-drug interaction contrast in complete-case analysis yielded an adjusted difference of - 0.424 (95% CI, -1.055 to 0.208; P = 0.188), with male precision constrained by sample size (7 male nifedipine users). In women with hypertension and heart failure with preserved ejection fraction, amlodipine use was associated with lower adjusted ln(BNP) levels than nifedipine use. These observational findings challenge the assumption of an interchangeable dihydropyridine class effect on myocardial wall stress, suggesting that individual pharmacological profiles-rather than uniform class-level equivalence-warrant attention in clinical evaluations.

PMID 42895302
Read full article →
PubMedBMC microbiology2026-10-19

Repurposing amlodipine, fluoxetine, and escitalopram as non-antibiotic adjuvants: in vitro enhancement of ciprofloxacin and fluconazole activity against multidrug-resistant bacterial and candida clinical isolates.

Alkhawlani Mohammed A MA, Al-Madhagi Wafa M WM, Alburyhi Mahmoud Mahyoob MM, Al-Kaf Ali Gamal AG et al.

Multidrug-resistant (MDR) Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans threaten treatment success, particularly in resource-limited settings. Repurposing licensed, inexpensive non-antibiotic drugs may provide a strategy for enhancing the activity of established antimicrobial agents. Clinical isolates from Sana'a, Yemen, and American Type Culture Collection (ATCC) reference strains were tested in vitro with amlodipine, fluoxetine, and escitalopram, individually and in dual or triple combinations with ciprofloxacin or fluconazole. Antimicrobial activity was evaluated using agar-well diffusion, broth microdilution minimum inhibitory concentration (MIC), minimum bactericidal or fungicidal concentration (MBC/MFC), and checkerboard fractional inhibitory concentration index (FICI) assays. Molecular docking with AutoDock Vina was used to explore plausible interactions with MurB (PDB 1HSK), LasR (PDB 3IX3), and CYP51 (PDB 5V5Z). Normal mode analysis (NMA) with iMODS was performed for selected fluoxetine-LasR and fluoxetine-MurB complexes as a preliminary structural-dynamics assessment. Fluoxetine produced inhibition zones of at least 27 mm across the tested organisms. Amlodipine produced larger zones against S. aureus and C. albicans than against P. aeruginosa, whereas escitalopram produced smaller zones overall. Checkerboard testing identified synergy (FICI ≤ 0.50) for selected combinations. Selected triple combinations reduced MIC values by 4- to 64-fold. The largest diffusion readouts were observed with ciprofloxacin + fluoxetine + amlodipine against S. aureus (101 mm), ciprofloxacin + fluoxetine + escitalopram against P. aeruginosa (88.5 mm), and ciprofloxacin + amlodipine + fluconazole against C. albicans (138.5 mm). Docking scores and NMA outputs provided hypothesis-generating structural context for the experimental findings. Antimicrobial enhancement was combination- and organism-dependent. Selected combinations showed checkerboard-defined synergy, whereas diffusion assays were interpreted as screening outcomes only. Docking and NMA findings were supportive and hypothesis-generating but did not establish target engagement or mechanism.

PMID 42894131
Read full article →
PubMedJournal of visualized experiments : JoVE2026-10-17

Sacubitril/Valsartan Improves Cardiovascular Outcomes in Elderly Patients with Coronary Artery Disease and Hypertension: A Retrospective Cohort Study.

Feng Miaolian M, Xie Ying Y

Elderly patients with concurrent coronary artery disease (CAD) and hypertension face elevated risks of cardiovascular events and require therapies that balance efficacy, safety, and tolerability. Sacubitril/valsartan has demonstrated benefits in heart failure management, but evidence regarding its long-term cardiovascular outcomes in this specific population remains limited. This retrospective cohort study enrolled 150 elderly patients with CAD and hypertension to compare the effects of sacubitril/valsartan versus amlodipine, both combined with conventional therapy. The primary endpoint was the incidence of major adverse cardiovascular events (MACE) over 12 months. Two MACE definitions were applied in this study. Primary analysis used our predefined composite endpoint, including aggravated heart failure and arrhythmia events. A sensitivity analysis adopted the conventional MACE definition (myocardial infarction, stroke, cardiovascular death, revascularization), excluding isolated ventricular premature beats. Secondary endpoints included blood pressure control, cardiac function parameters, and treatment-related adverse events. Results showed that patients treated with sacubitril/valsartan had a significantly lower incidence of MACE (10.26% vs. 27.14%, P = 0.008), superior blood pressure control, and improved left ventricular ejection fraction (LVEF) compared to the amlodipine group. Cox proportional hazards regression (Cox regression) analysis identified sacubitril/valsartan treatment as an independent protective factor against cardiovascular adverse events (hazard ratio (HR) = 0.38, 95% confidence interval (CI): 0.18-0.80, P = 0.011). Both regimens were well-tolerated, with no severe adverse events reported. These findings indicate that sacubitril/valsartan is an effective and safe therapeutic option for elderly patients with CAD and hypertension, reducing long-term cardiovascular risk while improving blood pressure control and cardiac function.

PMID 42891596
Read full article →
PubMedInternational journal of sports medicine2026-10-16

Analgesics and Exercise Performance in Pain-Free Situations: A Systematic Review and Meta-Analysis.

Franco-Alvarenga Paulo E PE, Brietzke Cayque C, Canestri Raul R, Vinícius Italo I et al.

Analgesics have been largely consumed as ergogenic in sports settings in pain-free situations. We summarized the collective evidence on their effects on exercise performance and exercise-induced pain through a systematic review and meta-analysis. The risk of bias and certainty of evidence of randomized placebo-controlled crossover studies were assessed using the Cochrane Risk of Bias 2 tool and the Grading of Recommendations Assessment, Development and Evaluation approach. A multilevel random-effects model compared the standardized mean difference among studies. Twenty-three studies investigating the effects of aspirin (n=4), ibuprofen (n=6), celecoxib (n=1), flurbiprofen (n=1), paracetamol (n=16) and tramadol (n=4) on exercise performance in pain-free situations showed a low risk of bias and moderate certainty of evidence. The very small effect of analgesics in grouped data (standardized mean difference=0.14; p=0.003) or data separated by exercise modalities (standardized mean difference=0.18; p=0.04) was unlikely to produce ergogenic benefits. Subgroup analysis evidenced that tramadol enhanced exercise performance in cycling exercises (standardized mean difference=0.38; p=0.03). No beneficial effect was observed in pain (standardized mean difference=-0.22; p=0.61). Analgesics commonly used in pain-free situations are unlikely to enhance exercise performance. Beneficial effects of tramadol on performance require confirmation in real-world contexts and different exercise modes.

PMID 42887522
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about amlodipine + celecoxib